Corvus Pharmaceuticals (NASDAQ:CRVS) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a research note released on Wednesday morning,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2025 earnings at ($0.43) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.44 EPS.

Corvus Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ:CRVS opened at $3.38 on Wednesday. The firm has a market capitalization of $217.19 million, a PE ratio of -3.63 and a beta of 0.91. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00. The business’s 50 day moving average is $4.61 and its 200-day moving average is $6.05.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06). On average, sell-side analysts predict that Corvus Pharmaceuticals will post -0.63 EPS for the current year.

Institutional Trading of Corvus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alpine Global Management LLC bought a new position in Corvus Pharmaceuticals during the fourth quarter worth about $62,000. Squarepoint Ops LLC lifted its position in shares of Corvus Pharmaceuticals by 712.5% during the 4th quarter. Squarepoint Ops LLC now owns 98,144 shares of the company’s stock worth $525,000 after buying an additional 86,064 shares during the period. Sphera Funds Management LTD. acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at $2,678,000. RTW Investments LP bought a new stake in Corvus Pharmaceuticals in the fourth quarter valued at $14,335,000. Finally, Man Group plc acquired a new position in Corvus Pharmaceuticals during the fourth quarter worth $73,000. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.